The Nuclear Medicine Department at the Baclesse Center has just received the European EARL Theranostics Level 2 accreditation, a distinction that recognizes its expertise in targeted internal radiation therapy (TIRT).
As the first department in Normandy and the eighth in France to achieve this level, this certification serves as a true guarantee of quality for patients undergoing TIRT.
Recognized expertise in innovative therapies
In light of the advancements in RIV over the past few years, this accreditation validates the quality of the images and treatments produced using beta and alpha emitters in our technical facilities.
From the earliest treatments with Iodine-131 to more recent innovations—such as Lutathera (2016), Xofigo, and Pluvicto (2023)—the department has successfully adapted its practices to remain at the forefront of therapeutic innovation.
Increased patient capacity
Thanks to the recent expansion of the RIV unit’s capacity, the Baclesse Center is now better equipped to care for patients receiving these targeted therapies.
A strong commitment to clinical research
The department is also fully committed to clinical research for new trials and the molecules that will shape the future of theranostics.
A collective achievement in the service of patients
This success is also the result of daily multidisciplinary collaboration among nuclear medicine physicians, medical physicists, radiopharmacists, and technologists in the nuclear medicine department; the nuclear medicine administrative team; nurses and nursing assistants on the 7th floor; radiation safety staff; and oncologists from the Center and throughout Normandy.
Together, day by day, we are building a form of precision medicine that is both innovative and compassionate.
